The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Avesthagen is a life science company pioneering the convergence between Food, Pharma and Population Genetics leading to Predictive Preventive Personalized Healthcare. The business model of Avesthagen is to combine IP & product development through in-house research and collaborations. Avesthagen has built and continues to build an integrated, systems biology approach of capabilities, products, infrastructure and technology that allows for and facilitates ‘cross talk’ between numerous disciplines, leading to unique and innovative solutions. They employ 450 people worldwide and are headquartered in Bangalore, India.

Suzhou Aijie Biotechnology Co., Ltd., established on 2001-12-24, Business scope includes research and development,Production Class II6840In vitro diagnostic reagents,And sell the products produced by the company.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

KOLON Life Science, Inc. engages in the manufacture and sale of pharmaceuticals and environment materials. It operates through the Pharmaceuticals and Environment Businesses. The Pharmaceutical business provides cell and gene therapeutics. The Environment business offers antibacterial and water treatment agents. The company was founded on April 21, 2000 and is headquartered in Seoul, South Korea.

Neurologix, Inc., a development stage company, engages in the discovery and development of therapeutic treatments for disorders of the brain and central nervous system. The company's treatments are designed as alternatives to conventional surgical and pharmacological treatments. It primarily focuses on gene therapy for treating Parkinson's disease, a neurodegenerative disorder; and epilepsy, a group of diseases associated with recurrent seizures, which is caused by periodic episodes of repetitive, abnormal electrochemical disturbance in the central nervous system, beginning in the brain. The company also focuses on the development of gene transfers for the treatment of neurodegenerative and metabolic disorders, including Huntington's disease, depression, and metabolic syndrome or genetically-based obesity. Neurologix, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

Milkhaus Laboratory, Inc. provides organic chemical products. Its products are used for urological health, skin care, wound care and other healthcare concerns. The company develops drugs based on the theory of systemic signaling, which postulates that therapeutic molecules can send genomic or cellular signals that disrupt the dysfunctional signals causing disease and allow the body to restore healthy signals. Milkhaus Laboratory was founded by Robert W. Middleton in 1993 and is headquartered in Providence, RI.

Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. It also develops and invests in stem cell and medical technology. The company was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.

Rhone Poulenc Rorer, a subsidiary of Solvay SA, is a French company that manufactures and distributs pharmaceutical products.

MeiraGTx UK II Ltd., a subsidiary of MeiraGTx Holdings Plc, is a company headquartered in London, UK. The firm develops novel gene-based therapies for retinal disorders that lead to vision loss. It was founded in 2014.

Dongguk University Industry-Academic Cooperation Foundation is for the promotion of tenants and entrepreneurship.

Vector Neurosciences, Inc. provides treatment for Parkinson disease. The company was founded by Michael Kaplitt and is headquartered in Wilmington, DE.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Plant Sensory Systems LLC operates as an agricultural biotechnology company. It develops technologies that improve agricultural performance and alleviate negative environmental impact to government, and pharmaceutical and agricultural biotech industries in the United States and internationally. The company was founded by Kathleen Turano and Frank Turano in and is headquartered in Baltimore, MD.

The Research Authority serves as the administrative and financial framework for research activities, scientific experiments and technical analyses carried out by Technion faculty, and TRDF staff. The missions of the Research & Development Division are: - Location, collection, processing and distribution of information concerning local and international research funding - Assistance in locating appropriate funding sources for Technion researchers - R&D information management services and in-campus marketing - Guidance and administrative services for Technion researchers in submitting research proposals to granting agencies and business entities - Management of contractual engagements with granting agencies and business entities - Contractual and budgetary administration of research grants and other accounts

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

A&G Pharmaceutical is a theranostics company creating and developing monoclonal antibodies to cancer-specific targets as a basis for novel therapeutic and diagnostic products. The company is currently advancing a near-term opportunity to develop and commercialize a line of diagnostic test kits that will improve early detection, diagnosis, and treatment of breast cancer based on GP88, a patented and proprietary growth factor discovered by A&G researchers. Concurrently, A&G's therapeutic division is pursuing development of anti-GP88 monoclonal antibody therapeutics for cancer. A&G's customized antibody service generates revenue to fund the drug development effort by accelerating the generation of novel, functional antibody therapeutics for leading pharmaceutical and biotechnology companies as well as federal laboratories. A&G has raised $3.5 million of equity capital and is located in Columbia, Md.